| Oct 9 |
Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
|
| Oct 9 |
Ocugen says the FDA has removed the clinical hold on the eye drug OCU200
|
| Oct 9 |
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
|
| Oct 2 |
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
|
| Sep 24 |
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
|
| Sep 17 |
Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3
|
| Sep 9 |
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
|
| Sep 5 |
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
|
| Sep 3 |
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 28 |
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
|
